Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1297-1307

  Gordon, Erlinda M ^b,e   Chan, Maria Teresa ^a,b   Geraldino, Nelson ^a,b,d   Lopez, Francisco F ^a,c   Cornelio, Gerardo H ^a,d   Lorenzo III, Conrado C ^a,c   Levy, John P ^e   Reed, Rebecca A ^e   Liu, Liqiong ^e   Hall, Frederick L ^e  

^a Department of Pathology ^*  (Philippines)

^b Asian Hospital and Medical Center Muntinlupa   (Philippines)

^c MAKATI MEDICAL CENTER   (Philippines)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e Epeius Biotechnologies Corporation   (United States)

Author keywords

Cancer gene therapy; Cancer immunotherapy; Cell cycle control; Cyclin G; Cytokine; GM CSF; Metastatic cancer; Nanotechnology; Pathotropic targeting

Indexed keywords

CYCLIN G; CYCLINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MOUSE; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANIMALS; CYCLINS; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MICE; NANOPARTICLES; NEOPLASMS;

EID: 34447276472     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1297     Document Type: Article

References (32)

1. Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA and Anderson WF: Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum Gene Ther 8: 2183-2192, 1997. (Pubitemid 28043556)
2. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993, 2000. (Pubitemid 30250115)
3. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S and O'Regan RM: Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7: 657-667, 2006. (Pubitemid 44143778)
4. Yih TC and Al-Fandi M: Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97: 1184-1190, 2006.
5. Groneberg DA, Giersig M, Welte T and Pison U: Nanoparticle-based diagnosis and therapy. Curr Drug Targets 7: 643-648, 2006.
6. Brigger I, Dubernet C and Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651, 2002.
7. Gordon EM, Liu PX, Zhen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW and Hall FL: Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 60: 3343-3347, 2000.
8. Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Liu L, Wei D, Groshen S, Hinton DR, Beart RW, Anderson WF and Hall FL: Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2001.
9. Gordon EM, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L and Hall FL: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 24: 177-185, 2004.
10. Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL: Pathotropic nanoparticles for cancer gene therapy. Rexin-G™ IV: three-year clinical experience. Int J Oncol 29: 1053-1064, 2006.
11. Xu F, Prescott MF, Liu PX, Chen ZH, Liau G, Gordon EM and Hall FL: Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing an improved cytocidal cyclin G1 construct. Int J Mol Med 8: 19-30, 2001.
12. Lenz HJ, Anderson WF, Hall FL and Gordon EM: Tumor site specific phase I/II evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 (dnG1) construct as treatment for colorectal carcinoma metastatic to liver. Hum Gene Ther 13: 1515-1537, 2002.
13. Pahre JN, Fuchs M, Levy J, Gordon EM and Hall FL: Molecular engineering of pathotropic vectors for cancer gene therapy. Bioproc J 2: 1-6, 2004.
14. Gordon EM and Hall FL: Nanotechnology blooms at last (Review). Oncol Rep 13: 1003-1007, 2005.
15. Gordon EM and Hall FL: A primer on pathotropic medicine. In: 100 Years of the FDA and the Future of Global Health. Russell K (ed). Brooklands New Media Ltd. Oswestry, Shropshire (In press).
16. Rosenberg SA and Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101: 14639-14645, 2004.
17. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Ross DC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL and Yeo CJ: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19: 145-156, 2001.
18. Simons JW, Mikhak B, Chang J, De Marzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Arter HB, Piantadosi S, Marsahall FF and Nelson WG: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168, 1999.
19. Emens LA, Reilly RT and Jaffee EM: Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12: 1-17, 2005.
20. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
21. Eager R and Nemunaitis J: GM-CSF gene-transduced tumor vaccines. Mol Ther 12: 18-27, 2005.
22. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ and Griffin CA: Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4: 194-203, 1998. (Pubitemid 28246955)
23. Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EMH, Wiernasz CJ, Merrill P, Gibson J, Ross M and Engelhard VH: Clinical and immunological results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21: 4016-4026, 2003. (Pubitemid 46606217)
24. Soiffer R, Hodi FS, Halushka F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M and Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21: 3343-3350, 2003. (Pubitemid 46606268)
25. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S and Lee PP: Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97: 186-200, 2003. (Pubitemid 36033878)
26. Brannon-Peppas and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56: 1649-1659, 2004. (Pubitemid 39177694)
27. Genova G, De Marco U, Xu H, Goins WF and Ahrens ET: A new transgene reporter for in vivo magnetic resonance imaging. Nat Med 11: 450-454, 2005.
28. Cohen B, Dafni H, Meir G, Harmelin A and Neeman M: Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 7: 109-117, 2005. (Pubitemid 40315988)
29. Cross D and Burmester JK: Gene therapy for cancer treatment: past, present and future. Clin Med Res 4: 218-227, 2006. (Pubitemid 44496015)
30. Emens LA: Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25: 415-443, 2006.
31. Copier J and Dalgleish A: Overview of tumor cell-based vaccines. Int Rev Immunol 25: 297-319, 2006.
32. + tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35: 808-816, 2004.